Heron Therapeutics, Inc. (HRTX)

NCM – Real Time Price. Currency in USD

0.96

+0.01 (0.93%)

At close: May 12, 2026, 4:00 PM EDT

0.97

+0.01 (0.76%)

After-hours: May 12, 2026, 6:58 PM EDT

04.05.2026

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

27.04.2026

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.

07.04.2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

26.02.2026

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

26.02.2026

Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

26.02.2026

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.

18.02.2026

Heron: Near The Bottom Of A Trading Range Despite Positives

HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031.

Videos

No Data

There is no data to display

Press releases

26.02.2026

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

09.01.2026

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron.

04.12.2025

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

CARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary and Full Report as published in Anesthesia and Analgesia (collectively, the “PONV Guidelines”).

04.11.2025

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million ZYNRELEF ® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE ® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate updates.

Heron Therapeutics, Inc. (HRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Heron Therapeutics, Inc. (HRTX)

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron: Near The Bottom Of A Trading Range Despite Positives

Videos

No Data

Press releases

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron: Near The Bottom Of A Trading Range Despite Positives

Videos

No Data

Press releases

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Search stocks

Heron Therapeutics, Inc. (HRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Heron Therapeutics, Inc. (HRTX)

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron: Near The Bottom Of A Trading Range Despite Positives

Videos

No Data

Press releases

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron: Near The Bottom Of A Trading Range Despite Positives

Videos

No Data

Press releases

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress